MedTrace Logo

A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension

NCT00853112 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2017-10-24

Study results available
· View outcomes & findings →

Summary

Study will assess PF-00489791 efficacy and safety in Pulmonary Arterial Hypertension (PAH)

Conditions

  • Hypertension, Pulmonary

Interventions

DRUG

PF-00489791

tablet form, 1 mg, single dose (Day 1)

DRUG

PF-00489791

tablet form, 2 mg, single dose (Day 1)

DRUG

PF-00489791

tablet form, 4 mg, single dose (Day 1)

DRUG

PF-00489791

tablet form, 10 mg, single dose (Day 1)

DRUG

PF-00489791

tablet form, 20 mg, single dose (Day 1)

DRUG

placebo

tablet form, single dose (Day 1)

DRUG

sildenafil

tablet form, 20 mg, single dose (Day 1)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United States
  • Canada
  • Germany
  • India
  • Russia
  • Spain
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00853112 on ClinicalTrials.gov